Literature DB >> 18330002

Intensive care unit management of patients with status epilepticus.

Thomas P Bleck1.   

Abstract

The intensive care unit management of status epilepticus focuses on patients who are refractory to initial treatment, who have an underlying condition that require critical care management, or who experience respiratory or cardiovascular complications of their therapies. The available data suggest that failure of a first-line anticonvulsant agent to terminate status should lead to the use of a definitive therapy in general anesthetic doses. Midazolam, propofol, and phenobarbital have been used most frequently; the place of newer agents (e.g., valproate, levetiracetam, or topiramate) remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18330002     DOI: 10.1111/j.1528-1167.2007.01352.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  5 in total

1.  Seizure treatment in transplant patients.

Authors:  Paul W Shepard; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

2.  New treatment options in status epilepticus: a critical review on intravenous levetiracetam.

Authors:  Eugen Trinka; Judith Dobesberger
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

Review 3.  Pediatric status epilepticus management.

Authors:  Nicholas S Abend; Tobias Loddenkemper
Journal:  Curr Opin Pediatr       Date:  2014-12       Impact factor: 2.856

4.  Tranexamic acid concentrations associated with human seizures inhibit glycine receptors.

Authors:  Irene Lecker; Dian-Shi Wang; Alexander D Romaschin; Mark Peterson; C David Mazer; Beverley A Orser
Journal:  J Clin Invest       Date:  2012-11-26       Impact factor: 14.808

5.  Seizure following general anesthesia for cystoscopy and urethral dilatation: A case report.

Authors:  Ahmed Sabry Elbashary; Khaloud A Alshwairikh; Raed Almaanie; Adel Alhazzani; Abdullah Alsufyani; Abdullah Almousa; Majed Alotaibi; Abdelazeem A Eldawlatly
Journal:  Saudi J Anaesth       Date:  2022-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.